The abstract is read at the publisher; the summary is JClub's.
In 8 consecutive patients with treatment-refractory juvenile-onset systemic sclerosis, autologous stem cell transplantation achieved 100% event-free survival at a median 30-month follow-up.
- Why it matters: Juvenile-onset systemic sclerosis causes vasculopathy and multiorgan fibrosis with early mortality, yet evidence for autologous stem cell transplantation in this rare pediatric-onset condition is limited.
- What they did: The study enrolled moderate-to-severe, drug-refractory patients receiving CD34+-selected ASCT with alemtuzumab, rituximab, antithymocyte globulin, total body irradiation, and thiotepa, then assessed outcomes at baseline and every 6 months up to 48 months.
- The result: All patients engrafted without treatment-related deaths or organ toxicities, with median modified Rodnan skin score improvement of 93% and 6-minute walk distance improvement of 13%, alongside multisystem stabilization and symptom improvement.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.